Basiliximab

Interleukin-2 Receptor Blocking Antibody — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Basiliximab is a drug in the Interleukin-2 Receptor Blocking Antibody class catalogued in DrugCentral. It was first approved by the FDA in 1998. Its mechanism of action is classified as Interleukin 2 Receptor Antagonists and Interleukin 2 Receptor-directed Antibody Interactions. DrugCentral lists 1 molecular target, including IL2RA. Recorded indications include Renal transplant rejection.

• Drug class: Interleukin-2 Receptor Blocking Antibody.
• Mechanism of action: Interleukin 2 Receptor Antagonists; Interleukin 2 Receptor-directed Antibody Interactions.
• Molecular targets: IL2RA (1 listed in DrugCentral).
• Indications: Renal transplant rejection.
• ATC code: L04AC02 (Interleukin inhibitors).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Renal transplant rejection

Mechanism & targets

• Mechanism of action (MoA): Interleukin 2 Receptor Antagonists; Interleukin 2 Receptor-directed Antibody Interactions
• Established pharmacologic class: Interleukin-2 Receptor Blocking Antibody

Molecular targets (1)

Target	Gene	Action	Activity
Interleukin-2 receptor subunit alpha	IL2RA	other	Kd 10.00

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
1998-10-09	EMA	—	—
1998-05-12	FDA	—	NOVARTIS

ATC classification

ATC code	Therapeutic hierarchy
L04AC02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Transplant rejection	2569.9
Kidney transplant rejection	2301.6
Cytomegalovirus infection	2240.0
Polyomavirus-associated nephropathy	1389.3
Complications of transplanted kidney	1107.4
Thrombotic microangiopathy	912.9
BK virus infection	839.5
Cytomegalovirus viraemia	706.7
Post transplant lymphoproliferative disorder	680.8
Multiple organ dysfunction syndrome	665.4
Delayed graft function	637.9
Mucormycosis	512.5

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Basiliximab used for?

DrugCentral lists the following indications for Basiliximab: Renal transplant rejection.

How does Basiliximab work?

Basiliximab is classified as Interleukin 2 Receptor Antagonists and Interleukin 2 Receptor-directed Antibody Interactions; its molecular targets in DrugCentral include IL2RA.

When was Basiliximab first approved?

Basiliximab was first approved by the FDA in 1998.

What drug class does Basiliximab belong to?

Basiliximab is in the Interleukin-2 Receptor Blocking Antibody class.

Sources

• DrugCentral drug card 4940 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201439 — compound record and bioactivity
• DrugBank DB00074 — drug record
• FDA UNII 9927MT646M — substance identity
• DailyMed: FDA labels for Basiliximab — current prescribing information (label search)
• UniProt P01589 (IL2RA) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.